While anti-TNF therapies are effective against psoriasis, 30%-50% of patients do not show an adequate response to these drugs. Different candidate-gene pharmacogenetics studies have identified single nucleotide polymorphisms that may predict anti-TNF drugs response in psoriasis. Nevertheless, only one paper has undertaken a pharmacogenomic approach failing to find significant biomarkers of biological drug response along the whole genome. Furthermore, most of the pharmacogenetic candidate biomarkers identified previously have not been confirmed in a different cohort of patients. The objective of this study was to find biomarkers that could predict anti-TNF drugs response along the whole genome and validate biomarkers identified previously. A genome-wide association study (GWAS) was performed using the Human Omni Express-8 v1.2 Beadchips in 243 psoriasis patients treated with anti-TNF drugs. This study was multicentric and did not interfere with clinical practice. Associations between single nucleotide polymorphisms (SNP) and PASI75 (a 75% reduction with respect to baseline PASI) at 3 months were evaluated. Imputation was performed using SNPs with R 2 > 0.7. There were two SNPs located in NPFFR2 that were close to the significant threshold of 5 × 10 −8. These data suggest that NPFFR2 might be associated with anti-TNF drug response. However, further How to cite this article: Ovejero-Benito MC, Muñoz-Aceituno E, Sabador D, et al. Genome-wide association analysis of psoriasis patients treated with anti-TNF drugs.

Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory comorbidities. 1,2 Severely affected patients are often treated with immune-modulating systemic drugs. 3,4 On 11 March 2020, the World Health Organization declared the 2019 novel coronavirus severe acute respiratory syndrome (SARS-Cov-2) epidemic to be a pandemic. The number of cases worldwide is increasing exponentially and poses a major health threat, especially for those who are elderly and immunocompromised, or have comorbidities. This also applies to AD patients on systemic immune-modulating treatment. In these days of uncertainty, reallocation of medical resources, curfew, hoarding and shutdown of normal social life, patients, caregivers and doctors ask questions regarding the continuation of systemic immunemodulating treatment of AD patients. The ETFAD decided to address some of these questions here: What do we recommend for AD patients treated with immune-modulating therapy at times of SARS-Cov-2 pandemic?